2. Search Result
Search Result
Results for "

SARS-CoV-2 E protein

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

2

Peptides

1

Natural
Products

15

Recombinant Proteins

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-N2183
    Baimaside
    3 Publications Verification

    Quercetin 3-O-sophoroside

    		 SARS-CoV Infection Neurological Disease
    Baimaside (Quercetin 3-O-sophoroside) is a flavonoid cholinergic function modulator that binds to SARS-CoV-2-related targets. Baimaside regulates the expression of cholinergic system-related proteins and acetylcholine levels, improves scopolamine-induced learning and memory impairment, protects hippocampal neurons, inhibits pollen protein fluorescence, and protects pollen DNA. Its biosynthesis is regulated by multiple enzymes. Baimaside is completely absorbed in rats, undergoes phase Ⅱ metabolism and gut microbiota decomposition, and inhibits the invasion and proliferation of SARS-CoV-2 and its variants, making it suitable for research related to Alzheimer's disease and COVID-19 .
    Baimaside
  • HY-153894
    SRX3177

    		CDK Epigenetic Reader Domain PI3K NF-κB SARS-CoV Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    SRX3177 is a triple inhibitor of CDK4/6, PI3K, and BRD4, with IC50s of <2.5 nM (CDK4), 3.3 nM (CDK6), 33 nM (BRD4 BD1), 89 nM (BRD4 BD2), 79 nM (PI3Kα), 83 nM (PI3Kδ), 3.18 μM (PI3Kγ) , respectively. SRX3177 blocks the interaction between the SARS-CoV-2 E protein and the BRD2/4 BD1 domain, restores E protein-attenuated NF-κB activity. SRX3177 exerts broad cytotoxic activity against cancer cells. SRX3177 can be used for the study of anti-SARS-CoV-2 and cancer .
    SRX3177
  • HY-175460
    SARS-CoV-2-IN-117

    		SARS-CoV Infection
    SARS-CoV-2-IN-117 (Compound C19) is a SARS-CoV-2 E protein inhibitor. SARS-CoV-2-IN-117 significantly inhibits SARS-CoV-2 E protein interaction with host ZO-1 PDZ2 domain. SARS-CoV-2-IN-117 has potent antiviral activity and significantly reduces viral replication. SARS-CoV-2-IN-117 can be used for COVID-19 research .
    SARS-CoV-2-IN-117
  • HY-176440
    BP-198

    		Virus Protease SARS-CoV PROTACs Infection
    BP-198 is an Mpro PROTAC degrader. BP-198 promotes the ubiquitination and degradation of Mpro. BP-198 has antiviral effects against SARS-CoV-2 (IC50: 11.8 μM) and has stronger activity against drug-resistant viruses. (Pink: target protein ligand (HY-176442); blue: E3 ligase ligand (HY-176441); black: linker (HY-W457968); E3 ligase-linker conjugate (HY-176443)) .
    BP-198
  • HY-168557
    SARS-CoV-2-IN-101

    		SARS-CoV Infection
    SARS-CoV-2-IN-101 (compound 10O) is a potent and orally active SARS-CoV-2 inhibitor with an EC50 value of 0.64 µM for HCoV-229E. SARS-CoV-2-IN-101 shows cyotoxicity. SARS-CoV-2-IN-101 decreases the expression of HCoV-229E N protein and RNA level. SARS-CoV-2-IN-101 shows broad-spectrum anti-coronaviral effect .
    SARS-CoV-2-IN-101
  • HY-P5642
    Retrocyclin-101

    RC-101

    		 Bacterial Ser/Thr Protease Influenza Virus HSV SARS-CoV Toll-like Receptor (TLR) Fungal HIV Flavivirus Infection Inflammation/Immunology
    Retrocyclin-101 (RC-101) is a synthetic cyclic θ-defensin, a broad-spectrum antimicrobial peptide with anti-pathogen (covering viruses, bacteria and fungi) activity and anti-inflammatory activity. Retrocyclin-101 exhibits significant inhibitory activity against HIV, SARS-CoV-2, flaviviruses, influenza viruses, HSV-1/2, Staphylococcus aureus and others. Retrocyclin-101 inhibits TLR4 and TLR2-mediated signal transduction and reduces pro-inflammatory cytokine expression .
    Retrocyclin-101
  • HY-161789
    PROTAC SARS-CoV-2 Mpro degrader-3

    		PROTACs SARS-CoV Virus Protease Infection
    PROTAC SARS-CoV-2 Mpro degrader-3 (Compound P2) exhibits antiviral activity through the degradation of the main protease (Mpro) of human coronaviruses (HCoVs) (DC50=27 μM). PROTAC SARS-CoV-2 Mpro degrader-3 inhibits the viral replication, with EC50 of 4.6 μM, 4.6 μM, and 0.71 μM, for human coronaviruses HCoV-229E, HCoV-OC43 and SARS-CoV-2, respectively. (Pink: ligand for target protein Mpro ligand 2 (HY-161791); Black: linker (HY-161792); Blue: ligand for E3 ligase (S,R,S)-AHPC (HY-125845)) .
    PROTAC SARS-CoV-2 Mpro degrader-3
  • HY-176441
    E3 ligase Ligand 66

    		Ligands for E3 Ligase Infection
    E3 ligase Ligand 66 is an E3 ligase ligand that can be used to recruit IAP proteins. E3 ligase Ligand 66 can be linked to SARS-CoV-2 Mpro ligand 1 (HY-176442) through a linker to form PROTAC BP-198 (HY-176440) .
    E3 ligase Ligand 66
  • HY-162295
    SARS-CoV-2-IN-83

    		SARS-CoV Infection
    SARS-CoV-2-IN-83 (compound C6E) has excellent activity against SARS CoV-2 spike protein .
    SARS-CoV-2-IN-83
  • HY-170515A
    (E),(Z)-RNF5 agonist 1

    		E1/E2/E3 Enzyme SARS-CoV Infection Neurological Disease Cancer
    (E),(Z)-RNF5 agonist 1 (Compound Analog-1) is a RNF5 agonist that can enhance the ubiquitination and degradation of SARS-CoV-2 E protein by RNF5. (E),(Z)-RNF5 agonist 1 effectively inhibits the replication of SARS-CoV-2 and significantly alleviates pulmonary pathological damage and systemic inflammatory response in mouse infection models. (E),(Z)-RNF5 agonist 1 has a strong cytotoxic effect on neuroblastoma and melanoma. (E),(Z)-RNF5 agonist 1 can be used for research on anti-cancer and anti-viral purposes .
    (E),(Z)-RNF5 agonist 1
  • HY-183761
    Antiviral agent 86

    		SARS-CoV Infection
    Antiviral agent 86 is an anti-coronavirus agent. Antiviral agent 86 acts as a binder of coronavirus non-structural protein 15 (nsp15), with a Ka value of 67 μM against human targets. Antiviral agent 86 inhibits the replication of HCoV-229E and SARS-CoV-2. Antiviral agent 86 exerts inhibitory effects at the post-entry lifecycle stage of coronaviruses in host cells and inhibits the formation of viral double-stranded RNA (dsRNA). Antiviral agent 86 exhibits an additive antiviral effect when used in combination with GS-441524. Antiviral agent 86 can be used in studies related to coronavirus infections .
    Antiviral agent 86
  • HY-P5642A
    Retrocyclin-101 TFA

    RC-101 TFA

    		 HIV SARS-CoV Influenza Virus Flavivirus HSV Bacterial Fungal Toll-like Receptor (TLR) Ser/Thr Protease Infection Inflammation/Immunology
    Retrocyclin-101 (RC-101) TFA is an artificially synthesized, cyclic-structured θ-defensin, a broad-spectrum agent with antimicrobial (covering viruses, bacteria, and fungi) activity and anti-inflammatory activity. Retrocyclin-101 TFA can inhibit the serine protease activity of ZIKV NS2B-NS3, with an IC50 of 7.20 μM. Retrocyclin-101 TFA has significant inhibitory activity against HIV, SARS-CoV-2, flaviviruses, influenza viruses, HSV-1/2, Staphylococcus aureus, etc. Retrocyclin-101 TFA inhibits the signal transduction mediated by TLR4 and TLR2, reducing the expression of pro-inflammatory cytokines .
    Retrocyclin-101 TFA

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: